Progress report: growth hormone in skeletal dysplasia

Horm Res. 1994;42(4-5):231-4. doi: 10.1159/000184198.


Growth hormone is not a logical treatment for the short stature associated with skeletal dysplasia because growth hormone concentrations are normal in these individuals. Short-term trials of growth hormone have demonstrated an increase in growth velocity in most of the skeletal dysplasias. Only in the skeletal dysplasia associated with Turner syndrome do we have data confirming that growth hormone treatment results in an increase in final height. Studies in achondroplasia and hypochondroplasia have demonstrated an increase in growth velocity which has been sustained for up to 4 and 6 years, respectively. In the long term, increased knowledge of the defects involved in skeletal dysplasia may lead us to improvements in both diagnosis and treatment.

Publication types

  • Clinical Trial
  • Review

MeSH terms

  • Achondroplasia / drug therapy
  • Achondroplasia / pathology
  • Adolescent
  • Adult
  • Age Factors
  • Body Height / drug effects
  • Bone Diseases, Developmental / drug therapy*
  • Bone Diseases, Developmental / pathology
  • Child
  • Child, Preschool
  • Female
  • Growth / drug effects
  • Growth Hormone / administration & dosage
  • Growth Hormone / therapeutic use*
  • Humans
  • Infant
  • Infant, Newborn
  • Male


  • Growth Hormone